Cover Image
市場調查報告書

DLL4 (Delta-Like Ligand 4):開發平台分析

Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 358353
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
DLL4 (Delta-Like Ligand 4):開發平台分析 Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Pipeline Review, H1 2016
出版日期: 2016年04月27日 內容資訊: 英文 48 Pages
簡介

本報告提供DLL4 (Delta-Like Ligand 4) 的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃相關資訊,以及最近的新聞和發表等訊息。

簡介

  • 調查範圍

DLL4 (Delta-Like Ligand 4) 概要

治療藥的開發

  • DLL4 (Delta-Like Ligand 4):開發中的產品 - 各開發階段
  • DLL4 (Delta-Like Ligand 4):開發中的產品 - 各治療範圍
  • DLL4 (Delta-Like Ligand 4):開發中的產品 - 各適應症

DLL4 (Delta-Like Ligand 4):開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

DLL4 (Delta-Like Ligand 在4):企業開發中的產品

DLL4 (Delta-Like Ligand 4):治療藥的評估

  • 單劑療法/聯合治療產品的評估
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

DLL4 (Delta-Like Ligand 4) 的治療藥開發企業

  • MedImmune, LLC
  • OncoMed Pharmaceuticals, Inc.
  • PharmAbcine, Inc.
  • Sevion Therapeutics, Inc.

DLL4 (Delta-Like Ligand 4) 的藥物簡介

DLL4 (Delta-Like Ligand 4):暫停中的計劃

DLL4 (Delta-Like Ligand 4):開發中止的產品

DLL4 (Delta-Like Ligand 與4):主要消息新聞稿

附錄

目錄
Product Code: GMDHC0017TDB

Summary

Global Markets Direct's, 'Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Pipeline Review, H1 2016', provides in depth analysis on Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) targeted pipeline therapeutics.

The report provides comprehensive information on the Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4)
  • The report reviews Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) Overview
  • Therapeutics Development
    • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Products under Development by Stage of Development
    • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Products under Development by Therapy Area
    • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Products under Development by Indication
  • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Products under Development by Companies
  • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Companies Involved in Therapeutics Development
    • MedImmune, LLC
    • OncoMed Pharmaceuticals, Inc.
    • PharmAbcine, Inc.
    • Sevion Therapeutics, Inc.
  • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Drug Profiles
    • demcizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-0639 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit DLL4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit DLL4 for Oncology and Inflammatory Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMP-305B83 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PMC-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Dormant Projects
  • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Discontinued Products
  • Delta-Like Ligand 4 (DLL4 or Drosophila Delta Homolog 4) - Featured News & Press Releases
    • Mar 17, 2016: OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)
    • Jan 22, 2016: OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium
    • Nov 09, 2015: OncoMed Presents Data From Anti-DLL4/VEGF Bispecific Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Nov 07, 2015: OncoMed Presents Immuno-Oncology Data for Combined Blockade of DLL4, VEGF and PD1 at the Society for Immunotherapy of Cancer Annual Meeting
    • Nov 04, 2015: OncoMed to Present Preclinical Data for the Combination of anti-DLL4/VEGF Bispecific plus anti-PD1 at the Society of Immunotherapy for Cancer Meeting
    • Oct 27, 2015: OncoMed to present preclinical results from OMP-305B83 at the AACR-NCI-EORTC International Conference
    • Aug 10, 2015: OncoMed Pharmaceuticals Updates Demcizumab Phase 1b Non-Small Cell Lung Cancer Survival Data
    • Jun 01, 2015: OncoMed Presents Data From Phase 1b Trial of Demcizumab in Pancreatic Cancer at the 2015 ASCO Annual Meeting
    • Jun 01, 2015: OncoMed Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual Meeting
    • May 28, 2015: OncoMed Pharmaceuticals to Review Key ASCO Data for Demcizumab During Conference Call on Tuesday, June 2, 2015
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by MedImmune, LLC, H1 2016
  • Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016
  • Pipeline by PharmAbcine, Inc., H1 2016
  • Pipeline by Sevion Therapeutics, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top